NbN3 12+
European College of Neuropsychopharmacology (ECNP)
iPhone対応
-
- 無料
iPhoneスクリーンショット
説明
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
新機能
バージョン 3.9.5
- Bug fixes.
評価とレビュー
アプリのプライバシー
デベロッパである"European College of Neuropsychopharmacology (ECNP)"は、アプリのプライバシー慣行に、以下のデータの取り扱いが含まれる可能性があることを示しました。詳しくは、デベロッパプライバシーポリシーを参照してください。
データの収集なし
デベロッパはこのアプリからデータを収集しません。
プライバシー慣行は、ご利用の機能やお客様の年齢などに応じて異なる場合があります。詳しい情報
情報
- 販売元
- ECNP Research and Scholarship Stichting (De ECNP Research and Scholarship Foundation)
- サイズ
- 23.4MB
- カテゴリ
- メディカル
- 互換性
-
- iPhone
- iOS 12.0以降が必要です。
- iPod touch
- iOS 12.0以降が必要です。
- Mac
- macOS 11.0以降とApple M1以降のチップを搭載したMacが必要です。
- Apple Vision
- visionOS 1.0以降が必要です。
- 言語
-
英語
- 年齢
- 12+ まれ/軽度な医療または治療情報
- Copyright
- © ECNP
- 価格
- 無料